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and consented to enter the study were randomly assigned to one of the two groups. Sixty-five patients were recruited, of which 31 were assigned to the stent arm and 34 to the TTA arm. Nine patients (14% of the total sample) who were still alive at one month failed to complete the health-related quality of life (HRQoL) questionnaires. Four of these patients received TTA therapy and five were treated with a stent. Thus, the losses to follow-up were 12% (TTA group) and 16% (stent group), respectively. In addition, 3 patients (10%) in the stent group did not complete dysphagia scores at one month.
Study design
The study was a randomised controlled trial. The number of centres participating in the study was not stated. The participants were randomised in blocks of 6. There was no indication of blinding. All of the patients were followed until death, although 3 TTA patients and 1 stent patient were still alive when the analysis was performed.
Analysis of effectiveness
The basis of the analysis was intention to treat. The primary health outcomes were survival, relief of dysphagia and quality of life. At the start of the trial, the groups were shown to be comparable in terms of median age, gender, median dysphagia score and tumour characteristics.
Effectiveness results
Survival in the TTA group was 125 days (range: 17 -546). This was significantly greater than the 68 days (range: 8 -602) in the stent group, (p<0.05). The mortality rate after TTA was lower than that after stent insertion, with an odds ratio of 0.6.
The median change in dysphagia score after one month was zero for both groups. A comparison of paired data at baseline and 1 month, and again at 2 and 3 months, was not significant for either group.
The HRQoL scores were analysed at one month and only for patients alive at this time.
The Hospital Anxiety and Depression questionnaire showed an increase in rates of depression for both groups. However, the rate of anxiety increased in the stent group and decreased in the TTA group.
The Short Form 36 showed that both groups experienced the same impaired (compared with the general public) quality of life at baseline. One month later, the TTA group results remained stable whereas the stent group experienced significantly poorer physical and emotional functioning, (p<0.05).
The EORTC-QLQ-C30 results also showed that the groups were similar at baseline and that the TTA group maintained their scores one month later. However, the stent group reported poorer emotional functioning.
One month later, there was no significant difference for either group in the dysphagia, deglutition or eating scores.
Clinical conclusions
Patients in the TTA group lived longer and maintained their HRQoL. As well as living for a shorter time, patients in the stent group experienced deterioration in their HRQoL. Functional palliation of dysphagia was not achieved in either group.
Measure of benefits used in the economic analysis
medical records. The hospital stay costs were obtained from a Hospital Trust and were based on charges made to fund holding general practitioners. For stent treatment, the cost comprised a basic cost of a radiograph session plus the cost of the stent. For TTA therapy, the estimated cost included the basic cost of an upper endoscopy plus the cost of the wave guides. The resource quantities and the costs were not reported separately. The study reported the median resource use for each patient group and the mean costs. The price year was not reported. Discounting was not relevant since the longest survival time at analysis was 602 days.
Statistical analysis of costs
The cost data were deterministic. No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not included.
Currency

UK pounds sterling ().
Sensitivity analysis
No sensitivity analysis was undertaken.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
For the stent group, the total mean cost was 3,378 (standard deviation, SD=8.7). Of this, 2,278 (SD=10.6) was for hospital stay and 1,100 (SD=5.7) was for therapy.
For the TTA group, the total mean cost was 6,235 (SD=13.4). Of this, 4,202 (SD=23.3) was for hospital stay and 2,031 (SD=3.3) was for therapy.
Twenty-five adverse events were observed. It would appear that the only cost ramification of these that was included was the impact on length of hospital stay and the need to administer a further procedure.
Synthesis of costs and benefits
Not applicable.
Authors' conclusions
Neither therapy provided satisfactory palliation of dysphagia. However, patients who underwent thermal tumour ablation (TTA) had a longer average survival and maintained their health-related quality of life (HRQoL) scores. In comparison, the stent group showed a deterioration in their HRQoL scores. The cost of TTA was nearly double that of stent therapy, owing to the need for repeated overnight hospitalisation of patients receiving ablative therapy.
CRD COMMENTARY -Selection of comparators
Although no explicit justification was given for the choice of the two technologies used, it would appear to represent current practice in the authors' setting. You should decide if the technologies represent current practice in your own setting.
